Acs Fall 2024 Vvd-130037 Vvd1300375. The bms team sought to develop a celmod® for ck1α degradation. Acs fall 2024 elevating chemistry candis lurline, we do not sell to patients.
Vividion therapeutics starts phase i clinical trial in advanced solid tumors with keap1 activator. The bms team sought to develop a celmod® for ck1α degradation.